ANIP EBITDA Growth
Ani Pharmaceuticals Inc · EBITDA Growth
ANIP EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported187.33%period ending
ANIP TTM EBITDA YoY % (15.57% → 187.33%)
Year-over-year change
High-resolution chart · PNG
ANIP ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 187.3259% | |
| 251.0305% | |
| 257.5625% | |
| 133.2236% | |
| -23.6953% | |
| -47.2127% | |
| -40.7887% | |
| -31.2651% | |
| 47.0722% | |
| 133.145% | |
| 325.7308% | |
| 2,125.5209% | |
| 1,010.0941% | |
| 461.2474% | |
| 703.5944% | |
| -118.7212% | |
| -125.5405% | |
| -139.364% | |
| -88.9221% | |
| 23.2474% | |
| 38.144% | |
| -12.6623% | |
| -53.7125% | |
| -71.1269% | |
| -68.1252% | |
| -41.0895% | |
| -11.3536% | |
| 19.497% | |
| 26.7893% | |
| 24.4428% | |
| 21.7343% | |
| 29.2277% | |
| 31.9891% | |
| 33.5019% | |
| 28.9844% | |
| 8.9193% | |
| 11.3456% | |
| 14.661% | |
| 10.2475% | |
| 3.9168% | |
| -1.3306% | |
| 27.4722% | |
| 65.8014% | |
| 175.1607% | |
| 459.6978% | |
| 301.7933% | |
| 1,664.8893% | |
| 724.4629% | |
| 176.3915% | |
| 149.346% | |
| 105.7652% | |
| 92.0949% | |
| 74.2085% | |
| 64.9629% | |
| 53.9268% | |
| 42.8189% | |
| 29.7025% | |
| 14.6279% | |
| -17.2822% | |
| -3.8682% | |
| -14.9664% | |
| -23.6561% | |
| -17.9874% | |
| -249.7588% | |
| -175.871% | |
| -130.851% | |
| -104.6809% | |
| 15.4579% | |
| -26.179% | |
| -68.9428% | |
| -109.4144% | |
| -637.9023% | |
| -391.348% | |
| -313.8739% | |
| -341.4481% | |
| 141.2787% | |
| 150.3469% | |
| 151.7776% | |
| 138.6635% | |
| 29.6678% | |
| 26.5368% | |
| 23.1226% | |
| 24.3607% | |
| -19.7% | |
| -53.9495% | |
| -74.6098% | |
| -103.9513% | |
| -109.6543% | |
| -105.2845% | |
| -86.0391% | |
| -60.1079% | |
| 2.6559% | |
| -0.8821% | |
| -17.0884% | |
| -27.9861% | |
| -96.8507% | |
| -27.9054% | |
| 10.2082% | |
| 16.3738% | |
| 15.566% |